Fourth-quarter earnings are shaping up to be the best of 2023, but there's a catch

Fourth-quarter earnings are shaping up to be the best of 2023, but there's a catch


Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 1, 2024. 

Brendan McDermid | Reuters

Here’s how big of a surprise corporate profits have been this earnings season: the fourth-quarter is now shaping up to be the best of 2023.

Despite ongoing macroeconomic concerns that have hampered demand and weighed on consumer sentiment, almost halfway into earnings season, profits are clearly coming in far better than anybody expected.

Helping companies’ bottom lines this round: easing input costs; more emphasis on cost controls and efficiencies; and significantly reduced expectations.

A plethora of significant earnings beats among some very important S&P 500 companies like Amazon, Meta, Apple, Chevron, Exxon Mobil, Merck and Bristol-Myers Squibb have moved the Q4 growth rate notably higher late this week.

LSEG, formerly Refinitiv, is now seeing a nearly 8% rise in earnings growth this season. That’s far better than the 4.7% expected just three weeks ago, right before the big banks reported results.

Stronger-than-expected results from three sectors are particularly notable:

  • Energy – 90% of the companies have beat earnings estimates, with profits coming in almost 14% above expectations
  • Health Care – 85% have beat on the bottom line, with earnings coming in nearly 11% above expectations
  • Tech – 84% have posted earnings beats, with earnings more than 5% above expectations

As for the S&P 500 as a whole, Q4’s current EPS growth rate of 7.8% exceeds the 7.5% growth seen in all of Q3 – and is now tops for the year.

Currently, 80% of S&P 500 earnings results have beat estimates, slightly higher than normal trends, and earnings have come in more than 6% above expectations — not quite the 7% to 8% upside seen in the previous two quarters, but still a very strong number.

One very important caveat: These strong figures come after earnings expectations tumbled going into the reporting season. Back on October 1, S&P 500 fourth-quarter earnings were expected to grow 11% year over year, according to LSEG.

Although the earnings picture has significantly improved since the start of 2024, results are still far below what Wall Street had hoped for a mere four months ago.

And, as good as Q4 results have been, there’s still no positive momentum looking forward. Both Q1 and full-year 2024 earnings estimates have come down since January 1 as many companies have issued cautious guidance this earnings season.

— Charts by CNBC’s Gabriel Cortes.



Source

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
Health

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers

The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients […]

Read More
Laura Modi, CEO and mom, is breaking one of the market’s biggest duopolies: Infant formula
Health

Laura Modi, CEO and mom, is breaking one of the market’s biggest duopolies: Infant formula

Laura Modi, co-founder and CEO of infant formula startup Bobbie, is on a mission to transform an industry that she says has been stagnant for decades, and shift the culture around how parents feed their babies. Modi, a former Airbnb executive, came up with the idea for Bobbie after the birth of her first child. […]

Read More
Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Health

Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers

U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. Win Mcnamee | Getty Images President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not […]

Read More